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I-131 uptake in the breast has been described with a variety of normal and pathologic
conditions. We present the case of a 38-year-old female who received 317 millicuries of
radioactive I-131 treatment for papillary thyroid carcinoma. Post-treatment scan demon-
strated I-131 uptake in an area of fat necrosis in the breast.
© 2016 the Authors. Published by Elsevier Inc. under copyright license from the University
of Washington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Planar radioactive iodine scans are routinely performed to
evaluate for metastatic disease from differentiated thyroid
cancer. Iodine uptake can be seen in multiple sites, in physio-
logic and pathologic processes apart from metastatic thyroid
cancer. We describe a case of I-131 uptake in an area of fat ne-
crosis in the breast, pointing out the challenges in diagnosis and
management of poorly differentiated papillary thyroid cancer.Case report
The patient is a 38-year-old female who presented to our
institution 2 years after her initial presentation and diagnosis,lared that no competing
i).
Elsevier Inc. under copy
se (http://creativecommoand after being managed by other providers. She has had a
history of hypothyroidism since age 25, and at age 36, she
detected a painful and palpable right sided neck mass. Ultra-
sound demonstrated a solid isoechoic 1.7 cm nodule with
multiple internal punctate echogenic foci, and ill-defined
margins. Fine needle aspiration was nondiagnostic. A sec-
ond fine needle aspiration showed thyroid carcinoma, which
could not be classified. The patient underwent right hemi-
thyroidectomy with neck dissection. Surgical pathology
revealed a 3.5 cm poorly differentiated papillary thyroid can-
cer, with extension into the perithyroid tissue andmuscles, as
well as lymphatic and venous invasion, and 5 of 6 positive
lymph nodes, which is consistent with an initial staging of
T4aN1b. There was no evidence of distant metastases
on staging positron emission tomography/computedinterests exist.
right license from the University of Washington. This is an open
ns.org/licenses/by-nc-nd/4.0/).
R a d i o l o g y C a s e R e p o r t s x x x ( 2 0 1 6 ) 1e72tomography (PET/CT). Because of the extensiveness of her
local disease, the patient underwent external beam radiation
therapy, followed by an extensive neck dissection, revealing
an additional 7 positive lymph nodes out of 27 resected. A
diagnostic whole body I-131 scan after administration of an
oral 4.13 mCi demonstrated a small focus of moderate activity
in the anterior neck along the midline, near the region of the
thyroid bed. The patient was then treated with 135.2 mCi of
radioactive iodine I-131 after Thyrogen stimulation, for
remnant ablation and presumably for local aggressive disease
with lymph node involvement. Post-treatment scan showed a
new focus of mildly increased activity over the right upper
chest, reported to be “concerning for a right upper lobe pul-
monary metastasis or conceivably a supraclavicular lymph
node metastasis” (Fig. 1). The inferred clinical opinion was
that this uptake could be due to lung metastases or due to
radiation-pneumonitis in the right upper lobe. CT chest was
then performed, demonstrating new pulmonary metastases
(Fig. 2), confirmed later with CT-guided biopsy as poorly
differentiated thyroid carcinoma. After 4 months, restaging
scans demonstrated mild interval increase in the size of the
pulmonary nodules, with concurrent gradual elevation of her
thyroglobulin levels (from 8.3 ng/mL before I-131 therapy, to
38 ng/mL). The patient presented to our institution at this
stage for a second opinion. Therewas a question regarding theFig. 1 e Initial post-treatment I-131 scan. Whole body planar vi
obtained 16 days following initial treatment with 135.2 mCi of
with minimal thyroid remnant (arrowheads), and focal uptake
posterior views (larger circles).potential benefit from a second radioactive iodine treatment,
so a whole body I-131 scan was performed in an outside
institution, and reported to have “evidence of iodine avidity in
her pulmonary metastases”. The consensus decision among
the patient, the endocrinologist, and the nuclear medicine
physicians was to administer a second treatment dose of I-131
for treatment of pulmonary metastatic disease, based on
whole body dosimetry (Memorial Sloan Kettering method). A
dose of 3.1 mCi of oral I-131 was administered for whole body
dosimetry. Images demonstrate only faint lung uptake,
greater on the right side than the left (Figs. 3 and 4). Single-
photon emission computed tomography (SPECT) was not
performed, as this was a dosimetry study and the pretherapy
scan was performed and demonstrated iodine uptake in the
lung metastases. The dosimetry estimated 5402.6 mCi of oral
I-131 to deliver 80 mCi retained dose in the lungs at 48 hours,
and 344.2 mCi to deliver 200 rads to the bonemarrow.With all
the considerations, given there were known pulmonary nod-
ules on the CT chest, and after discussion with the referring
endocrinologist, 300 mCi I-131 were prescribed for Thyrogen-
driven therapy. The patient presented for her second radio-
active I-131 treatment, and received a dose of 317.3 mCi. A
post-treatment I-131 scan was performed 9 days following
administration of the therapeutic dose, demonstrating focal
uptake in the right anterior chest, but no definite uptake in theews (left) and spot views of the head, neck, and chest
I-131. There is intense focal uptake in the neck consistent
in the right anterior chest (circles), seen faintly on the
Fig. 2 e Pulmonary metastases on chest computed
tomography (CT). Reconstructed 2 cm thick maximum
intensity projection (MIP) image of chest CT demonstrating
small bilateral pulmonary nodules (arrows) in random
distribution, typical for miliary metastases. Biopsy was
consistent with metastasis from patient's primary thyroid
cancer. These were new when compared with a prior
staging positron emission tomography (PET) scan.
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images localized the uptake in the right anterior chest to an
area of fat necrosis in the right breast (Fig. 6), but failed to
confirm any I-131 uptake in the metastatic pulmonary nod-
ules. Review of patient's prior imaging studies demonstrate
that the area of fat necrosis was also present on staging flu-
orodeoxyglucose (FDG)-PET scan performed 2 years earlier
(Fig. 7), and was reported on prior mammogram, along with
postreduction changes. Thyroglobulin levels started to rise 6
months following the external beam radiation, and continued
to increase gradually. CT chest was repeated 4 months
following the second radioactive iodine therapy, and it
demonstrated worsening metastatic disease with multiple
new and enlarging pulmonary nodules, as well as several
pleural metastatic deposits.Discussion
In this presented case, wewill allude briefly into several issues
following the main discussion about radioiodine uptake in fat
necrosis of the breast.
Radioactive iodine in the chest could be in multiple sites
other than the lungs, and even in the lungs it could be seen
with different pathology aside from metastatic lung disease.
On planar imaging, iodine uptake in the chest may be internal
or external because of contamination. Internal uptake can be
classified by etiology as physiologic, pathologic, or internal
retention [1]. Radioactive iodine uptake has been described in
many normal organs as well as a variety of pathologic pro-
cesses. In the chest, internal activity can be classified
anatomically, within the soft tissues, breast, ribs, heart, peri-
cardium,mediastinum, pleura, or lung parenchyma [2]. Iodine
uptake in soft tissues and has been reported with lymphoe-
pithelial cyst, skin burn [3], skin wound [4], and even in a
psoriatic plaque [5]. Iodine uptake may be in the rib from a
benign [6] or metastatic bone lesion, whether from papillary
thyroid cancer or a different primary [7]. Iodine uptake in thepleura and mediastinum has also been described in pleuro-
pericardial cyst, pericardial effusion [8], esophageal retained
saliva, Barrett's esophagus, or Zenker diverticulum, and is
potentially possible in ectopic mediastinal thyroid tissue that
has excessively migrated [7]. Myocardial iodine uptake has
been described after myocardial infarction [9]. In the lung
parenchyma, iodine uptake can be due to a primary lung
malignancy, metastatic disease, or inflammatory lung disease
[8,10]. Note that this is not a comprehensive list of sites of
accumulation of radioactive iodine, and several extensive
review articles are available covering this topic.
Focal uptake in the chest is not typical with metastatic
pulmonary disease, given that papillary thyroid cancer tends
to spread in a miliary pattern or diffuse micronodules when it
metastasizes to the lungs. When focal uptake is noted in the
chest, it might be wise to order oblique and/or lateral views to
see whether this uptake localizes within or outside the
thoracic cage. Alternatively, SPECT CT can be of value.
Iodine uptake has been described in the breast tissue in
lactating and nonlactating females [11,12]. In the lactating
breast, as well as in the thyroid gland, sodium-iodide sym-
porter (NIS) mediates iodine uptake [13]. NIS expression in
most thyroid cancers is less than that of normal thyroid gland;
this iswhythyroidcancersusuallyappearascoldnodules.Still,
around80%ofwell-differentiated thyroidcancershaveenough
NIS expression to facilitate iodine uptake in radioactive iodine
treatment [13]. NIS is also overexpressed in the lactating breast
[14]. Prolactin plays a role in induction of NIS [13], and bilateral
breast uptake has been described in a woman with hyper-
prolactinemia from a pituitary microadenoma [15].
Iodine uptake in the nonlactating breast has been
described in 6% of womenwho had radioiodine scans, and the
etiology remains poorly understood [12]. Radioiodine uptake
in the breast can be seen with gynecomastia, supernumerary
breasts, and lactational duct cyst or galactocele [7].
Fat necrosis is a non-suppurative inflammatory process
that is being increasingly encountered incidentally on
mammography or other imaging modalities [16]. Fat necrosis
can occur after trauma, diagnostic breast interventions, or
breast surgery [17]. The inflammation is followed by a repar-
ative phase, and is surrounded by a rim of fibroblasts, that
may subsequently produce rim calcifications [16,18]. FDG up-
take is expected in areas of active inflammation, and has been
specifically described in fat necrosis of the breast [17]. Iodine
uptake, on the other hand, has not been specifically associated
with fat necrosis of the breast, although it has been described
in inflammation and scars, as detailed earlier. An interesting
observation when comparing the PET scan in the reported
case to the SPECT, shows that FDG accumulation is mostly
along the periphery of the area of fat necrosis, which is
expected as it is probably related to the surrounding inflam-
mation or fibroblastic activity [19]. Iodine accumulation,
however, seems to be in the center of the fat necrosis. This
observation might pave the road to further understanding of
the etiology of iodine uptake in fat necrosis of the breast as a
possible future work in cellular biology.
There have been some controversial aspects in the man-
agement of the reported patient. The patient is a 38-year-old
female with poorly differentiated papillary thyroid carci-
noma, and multiple bilateral metastatic pulmonary nodules.
Fig. 3 e Diagnostic I-131 scan, 48 hours. Whole body planar scans were performed 48 hours following oral administration of
3.1 mCi of I-131 for a diagnostic study. There is apparent faint uptake overlying the chest on posterior and anterior views,
compared with the adjacent soft tissues.
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well-established treatment option in subgroups of patients
with well-differentiated papillary, follicular, and Hurthle cell
carcinoma of the thyroid. In cases of anaplastic carcinoma,
radioactive I-131 treatment is not recommended. Poorly
differentiated thyroid carcinoma falls histologically on thespectrum between well-differentiated and anaplastic carci-
noma [20]. In contrast to anaplastic carcinoma, poorly
differentiated thyroid carcinomas tend to produce thyro-
globulin, and up to two-thirds do concentrate iodine [21]. This
indicates a potential role for radioactive I-131 therapy on a
case-by-case basis. In a review from Memorial Sloan-
Fig. 4 e Diagnostic I-131 scan, 96 hours. Whole body planar scans were performed 96 hours following oral administration of
3.1 mCi of I-131. Two anterior views (left) and 2 posterior views (right) are presented with 2 different display settings. The
chest uptake is even less conspicuous compared with images taken at 48 hours (shown in Fig. 3).
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poorly differentiated thyroid carcinomas display radioactive
iodine avidity, and that most authors advocate for the use of
radioactive iodine therapy in this setting. From the same
institution, an argument was made that radioactive iodine
ablation should be offered routinely to patients with poorly
differentiated thyroid cancers, because of the aggressiveness
of this disease, “giving it a shot”, despite the fact that many
patients will have persistent or recurrent disease [23]. More
recently, tyrosine kinase inhibitors have proven benefits in
lung metastases from radioiodine-resistant thyroid can-
cer [24]. Currently, Sorafenib is the FDA-approved for
radioiodine-resistant metastatic differentiated thyroid can-
cer, but it has a high rate of adverse events [25]. Because these
scenarios are not very common, there are no specific guide-
lines and management options in cases of poorly differenti-
ated thyroid cancer remain a topic of controversy and a
clinical challenge.In our reported case, the patient had her pretreatment
uptake scan performed in another institution, and the
findings were consistent with radioiodine uptake in the
chest. As the patient had also had known metastatic pul-
monary nodules, the study was officially interpreted as
positive for iodine uptake within the lung metastases, and
the decision to treat was based on this interpretation. The
second treatment was carried out at our institution pri-
marily after communication from the clinician that the
lung metastases were positive for iodine uptake. Retro-
spectively, while we reviewed the records from the other
hospital, and compared with the SPECT CT that we have
performed, the chest uptake was actually in the area of fat
necrosis in the right breast and not within the chest cavity
or the lung metastases. Post-treatment SPECT confirmed
that the disease in the lungs was not iodine avid, and the
progression of the lung nodules after a few months also
support this conclusion.
Fig. 5 e Second post-treatment I-131 scan. Whole body planar scans were performed 9 days following oral administration of
317 mCi of I-131. Two anterior and 2 posterior whole body views in 2 different display settings demonstrate focal uptake in
the right hemithorax anteriorly (arrowheads), with faint shine-through on the posterior projection (circles).
Fig. 6 e Single-photon emission computed tomography/CT demonstrating focal I-131 uptake in the right breast. The
radiotracer uptake is localized to a fat containing well-defined lesion in the right breast, with surrounding rim of linear soft
tissue and discontinuous linear calcifications, consistent with fat necrosis (asterisks).
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Fig. 7 e PET/CT demonstrating focal fluorodeoxyglucose
(FDG) uptake in the right breast. Fused axial images from a
PET/CT performed 2 years before the SPECT/CT (shown in
Fig. 6). There is avid FDG uptake within the periphery of the
fat necrosis in the right breast (arrowheads).
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Poorly differentiated thyroid carcinoma represents a clinical
challenge. Planar images for evaluation of metastatic disease
should always be interpreted carefully, and any cases of
ambiguous uptake should be investigated by SPECT-CT
whenever possible. Nuclear medicine physicians and radiol-
ogists should be aware of physiologic and pathologic sites of
iodine uptake. It is highly recommended to obtain all outside
records of the patient before administering radioactive iodine
therapy, especially for high doses.r e f e r e n c e s
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